| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 791 | $83.52 | $66,063.37 | -3.9% | |
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 920 | $83.54 | $76,859.38 | -0.6% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,225 | $88.09 | $107,910.57 | -3.3% | |
| Feb 5, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 4,289 | $23.00 | $98,647.00 | -7.6% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 1,272 | $88.14 | $112,118.58 | -3.6% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,357 | $88.01 | $119,426.71 | -3.6% | |
| Feb 5, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 11,397 | $23.18 | $264,166.50 | -24.1% | |
| Feb 5, 2019 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 231,566 | $78.08 | $18,079,654.39 | -25.1% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 3,809 | $88.12 | $335,667.92 | -1.1% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 7,614 | $88.16 | $671,216.18 | -0.6% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 2,445 | $88.14 | $215,504.88 | -0.7% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 2,725 | $88.12 | $240,125.44 | -0.7% | |
| Feb 4, 2019 | MRK Merck & Co., Inc. | Glocer Thomas H | Director | Sell | 10,000 | $75.96 | $759,590.00 | -66.2% | |
| Feb 4, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 38,200 | $1.58 | $60,478.00 | - | |
| Feb 1, 2019 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $5.86 | $58,600.00 | -1.1% | |
| Feb 1, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | CEO | Sell | 30,085 | $41.54 | $1,249,831.20 | -1.0% | |
| Feb 1, 2019 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $32.73 | $32,730.00 | -100% | |
| Feb 1, 2019 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 37,530 | $17.17 | $644,372.89 | -5.1% | |
| Jan 31, 2019 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 250,000 | $16.00 | $4,000,000.00 | -7.9% | |
| Jan 31, 2019 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 42,624 | $17.49 | $745,468.19 | -57.7% | |
| Jan 31, 2019 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP &President, Lilly Int'l | Sell | 4,000 | $120.00 | $480,000.00 | -8.8% | |
| Jan 31, 2019 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 3,060 | $16.56 | $50,676.66 | -3.8% | |
| Jan 31, 2019 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 7,651 | $16.48 | $126,088.48 | -5.0% | |
| Jan 30, 2019 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 9,564 | $16.47 | $157,497.08 | -1.5% | |
| Jan 30, 2019 | PAHC Phibro Animal Health Corp | Bendheim Daniel M | Exec. VP, Corporate Strategy | Sell | 9,780 | $31.34 | $306,478.30 | -100% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.